p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.
about
Neural immune modulation and immunotherapy assisted by focused ultrasound induced blood-brain barrier openingTau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.Interactions of pathological proteins in neurodegenerative diseases.Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approachNPT088 reduces both amyloid-β and tau pathologies in transgenic miceEmerging Diagnostic and Therapeutic Strategies for Tauopathies.Tauopathies: Mechanisms and Therapeutic Strategies.Human Truncated Tau Induces Mature Neurofibrillary Pathology in a Mouse Model of Human Tauopathy.Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice.Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies.Clearing the way for tau immunotherapy in Alzheimer's disease.Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein.
P2860
Q30374364-38252D03-873D-4C34-908C-6F54CA7B55B0Q36558485-D632C98E-D170-4E19-8E61-E0D5D5523792Q37561154-0E9C2D86-1C2E-43AC-8B78-E35E649AF532Q37610545-DB6F1CA8-9756-4604-89E1-602563685EF1Q39236779-EF5EE996-1756-4486-83F3-8D7EBACEA008Q41196178-A2D5A13B-FF95-4C6D-94BE-01B9C4F8CC40Q41629521-1AD05326-810F-43BD-90E3-44BCFD2A3352Q42656183-E8EF89FB-EFD6-4D09-80AA-B5CCD69C627FQ45870549-FDAE8257-40FA-45CC-BDAD-B127D0AD78C1Q47253592-48AB1B57-7848-45D5-9E30-E75B1FAC62B3Q48547546-5C4C8102-D91C-4DDF-B27C-9C8DE6067E77Q50045202-07FBEB51-2368-4F95-95D6-0ECE284BC45BQ50532471-48D2EEA8-1D36-468C-8FC4-46CA3B41320AQ53468218-05CDECC9-5AFF-410C-BE68-5BECAAA68167Q55118610-69233352-01EE-49D0-A0A0-6072D869B9FF
P2860
p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.
@ast
p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.
@en
type
label
p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.
@ast
p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.
@en
prefLabel
p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.
@ast
p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.
@en
P2093
P2860
P1433
P1476
p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.
@en
P2093
Dave Cheng
Frank M LaFerla
Ken C Walls
Rahasson R Ager
Vitaly Vasilevko
P2860
P304
P356
10.1016/J.NEULET.2014.05.047
P407
P577
2014-06-02T00:00:00Z